ISRCTN45605573已完成3 期
A multicentre phase III randomised double-blind placebo-controlled trial of pravastatin added to first-line chemotherapy in patients with non-small cell lung cancer (LungStar 2 trial)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histological or cytological-confirmed NSCLC
- •2. Stage IV disease or stage IIIB disease that is unsuitable for radio-chemotherapy
- •3. Presence of one or more measurable lesions (by Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
- •4. Estimated life expectancy of at least 12 weeks
- •5. Performance status 0, 1 or 2
- •6. Aged 18 or over
- •7. Patients must be able to give informed consent
- •8. Adequate haematological function (absolute neutrophil count [ANC] greater than 1.5 x 10^9 /l, platelets greater than 100 x 10^9 /l, and haemoglobin greater than 9 g/dl)
- •9. Adequate renal function: ethylenediaminetetraacetic acid (EDTA) based glomerular filtration rate of greater than 55 ml/min or a 24-hour creatinine clearance of greater than 60 ml/min
- •10. Adequate hepatobiliary function: serum bilirubin less than 1.5 times the upper limit of normal (ULN) and serum aspartate aminotransferase (AST) and/or alanine transaminase (ALT) less than 2.5 x ULN in patients without liver involvement or less than 5.0 x ULN in patients with liver metastases
- •11. Patient compliance and geographic proximity allowing for adequate follow-up
- •12. Female patients potentially able to bear children should use an approved contraceptive method (intrauterine device [IUD], birth control pills or barrier device) during and for three months after the study. All male patients should take adequate contraceptive precautions during and up to two months after the study
- •13. Written informed consent prior to admission to this study
排除标准
- •1. Presence of central nervous system metastases
- •2. Prior chemotherapy or radiotherapy for this disease
- •3. Protocol chemotherapy should start after randomisation (except for example when a patient needs to start chemotherapy urgently, randomisation may occur at a maximum of one working day after day 1 of cycle 1 but consent to the trial must always be obtained prior to starting chemotherapy)
- •4. Creatinine kinase greater than or equal to 5 x ULN
- •5. Patients treated with statins (e.g. simvastatin, pravastatin, atorvastatin) within one year prior to randomisation
- •6. Patients treated with fibrates (e.g. bezofibrate, gemfibrozil, fenofibrate) within four weeks prior to randomisation
- •7. Patients on cyclosporine
- •8. Hypersensitivity to docetaxel, carboplatin, cisplatin or pravastatin or any of their excipients
- •9. Evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial
- •10. Evidence of uncontrolled infection
- •11. Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study
- •12. A history of prior malignant tumour, unless the patient has been without evidence of disease for at least three years or the tumour was a non-melanoma skin tumour or early cervical cancer
- •13. Pregnancy and lactation; effective contraception is mandatory for all patients of reproductive potential if sexually active whilst in the study. Contraception should continue for one year post completion of all chemotherapy or radiotherapy and a further 28 days after cessation of pravastatin/placebo
研究者
相似试验
尚未招募
3 期
Phase III Study Comparing Gabapentin-Duloxetine Capsules to Pregabalin-Duloxetine Capsules for Neuropathic PaiCTRI/2024/07/071354Mr Surender Arora
进行中（未招募）
不适用
IgNITE: Immunoglobulin in the treatment of encephalitisMedDRA version: 17.1Level: LLTClassification code 10014594Term: Encephalitis infectionSystem Organ Class: 100000004862EncephalitisEUCTR2014-002997-35-GBniversity of Oxford308
已完成
3 期
Phase III clinical trial comparing safety and efficacy of BCD-022 (CJSC BIOCAD, Russia) used with paclitaxel to Herceptin® used with paclitaxel in the first-line treatment of HER2 positive metastatic breast cancer patients.CTRI/2014/07/004722BIOCAD INDIA PVT LTD206
进行中（未招募）
不适用
A randomized, double-blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy - AvailAdvanced or recurrent non-squamous non-small cell lung cancer.MedDRA version: PTLevel: 7.0Classification code 10061873EUCTR2004-000864-29-CZF. Hoffmann-La Roche Ltd.1,050
进行中（未招募）
1 期
A randomized, double-blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy - AvailEUCTR2004-000864-29-DEF. Hoffmann-La Roche Ltd.1,050